StockData

Connect Biopharma vs Upstream Bio

CNTB and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNTB and UPB compare

Connect Biopharma grew revenue faster over the last twelve months (50.3% versus 2.5% for Upstream Bio).

Connect Biopharma keeps more of each dollar of sales as profit, with a net margin of −2336% compared with −5712% at Upstream Bio.

Upstream Bio scores higher on the StockData Score (8 against 6 for Connect Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNTBUPB
Size and price
Market cap–$152M
Share price$0.677$2.78
Change, 1 year−57.9%−88.3%
Change, 5 years−86.8%–
Beta (5Y)0.531.28
Employees–75
StockData Score
Total score68 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score01 (better)
Health score56 (better)
Dividend score00
Valuation
P/S–53.1×
P/B–0.7×
Growth
Revenue growth (TTM)50.3% (better)2.5%
Profitability
Operating margin−2384% (better)−6116%
Net margin−2336% (better)−5712%
FCF margin−2053%–
Return on equity−141%−53.5% (better)
Return on invested capital–−846%
Financial health
Debt / equity0.000.00
Current ratio2.3720.45 (better)
Altman Z-score–3.80
Piotroski F-score11
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions22.1%92.3%
Held by insiders31.6%8.6%
Insider net buying, 12 months$4.4M (better)−$105K
Short interest, % of float–7.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.